Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arovella Therapeutics Limited ( (AU:ALA) ) has shared an announcement.
Arovella Therapeutics Limited has issued 371,187 ordinary shares without disclosure under the Corporations Act, complying with relevant legal provisions. This move is part of the company’s strategic efforts to strengthen its financial position and support its ongoing development of innovative cancer therapies, potentially enhancing its market presence and stakeholder value.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd is a biotechnology company specializing in the development of invariant natural killer T (iNKT) cell therapy platforms to treat blood cancers and solid tumors. Their lead product, ALA-101, utilizes CAR19-iNKT cells targeting CD19, an antigen found on various cancer types. The company is also advancing into solid tumor treatments with technology licensed from Sparx Group.
Average Trading Volume: 1,319,006
Technical Sentiment Signal: Sell
Current Market Cap: A$96.06M
See more data about ALA stock on TipRanks’ Stock Analysis page.